Bristol-Myers Inks Up to $15 Billion Licensing Deal With Hengrui
Bristol-Myers Squibb Co. inked a collaboration and licensing deal with Jiangsu Hengrui Pharmaceuticals Co. that could be valued at as much as $15.2 billion, as the US drugmaker seeks to leverage China’s efficiency in early development.
Original Source
Read the full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.